Top

Published in:

01-09-2020 | Colchicine | Observational Research

Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic

Authors: Fatih Haslak, Mehmet Yildiz, Amra Adrovic, Sezgin Sahin, Oya Koker, Ayten Aliyeva, Kenan Barut, Ozgur Kasapcopur

Published in: Rheumatology International | Issue 9/2020

Abstract

Concerns regarding the comorbidity as a significant risk factor for Coronavirus Disease-2019 (COVID-19), gave rise to an urgent need for studies evaluating patients with chronic conditions such as autoinflammatory diseases (AIDs). We prepared a web-based survey investigating the clinical findings and contact histories among pediatric patients with AIDs. Confirmed COVID-19 cases, patients with contact history and those with symptoms which were highly suggestive of COVID-19 were called via phone or recruited to a video or face to face appointment. Data of AIDs were obtained from their medical records, retrospectively. Laboratory and screening findings were confirmed by our national health registry website. There were 404 patients (217 female) eligible for the enrollment. During pandemic, 375 (93%) were on colchicine treatment and 48 (11.8%) were receiving biologic treatment. Twenty-four out of 404 patients were admitted to hospital due to COVID-19 suspicion. Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) was identified through rhinopharyngeal swabs in seven patients, six of whom were only on colchicine treatment. Only one patient with no finding of any severe respiratory complications was hospitalized. All of seven patients recovered completely. Among patients on biologic drugs, neither a symptom nor a positive polymerase chain reaction test for COVID 19 was detected. In conclusion, pediatric patients with AIDs, those receiving biologic treatment and/or colchicine, may not be at increased risk for neither being infected nor the severe disease course.

Haşlak F, Yıldız M, Adrovic A, Barut K, Kasapçopur Ö (2020) Childhood rheumatic diseases and COVID-19 pandemic: an intriguing linkage and a new horizon. Balkan Med J. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.4.43 CrossRefPubMedPubMedCentral

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395(10223):507–513CrossRef

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan China. JAMA 323(11):1061–1069CrossRefPubMedPubMedCentral

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39(7):2055–2062. https://doi.org/10.1007/s10067-020-05073-9 CrossRefPubMed

Hedrich CM (2020) COVID-19—considerations for the paediatric rheumatologist. Clin Immunol (Orlando, FL) 214:108420. https://doi.org/10.1016/j.clim.2020.108420 CrossRef

Ludvigsson JF (2020) Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 109(6):1088–1095CrossRefPubMed

Gasparyan AY, Misra DP, Yessirkepov M, Zimba O (2020) Perspectives of immune therapy in Coronavirus disease 2019. J Korean Med Sci 35(18):e176–e176. https://doi.org/10.3346/jkms.2020.35.e176 CrossRefPubMedPubMedCentral

Korkmaz MF, Türe E, Dorum BA, Kılıç ZB (2020) The epidemiological and clinical characteristics of 81 children with COVID-19 in a pandemic hospital in Turkey: an observational cohort study. J Korean Med Sci 35(25):e236. https://doi.org/10.3346/jkms.2020.35.e236 CrossRefPubMedPubMedCentral

Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D (2020) Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol 55(5):1169–1174CrossRefPubMedPubMedCentral

10.

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79(5):667–668CrossRefPubMed

11.

Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, Zhan L-Y, Jia Y, Zhang L, Liu D, Xia Z-Y, Xia Z (2020) Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 21:100331–100331. https://doi.org/10.1016/j.eclinm.2020.100331 CrossRefPubMedPubMedCentral

12.

Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, Zhang Y, Zhang H, Jia R, Liu P, Wang X, Ge Y, Xia A, Tian H, Chang H, Wang C, Li J, Wang J, Zeng M (2020) A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa198 CrossRefPubMedPubMedCentral

13.

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S (2020) Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. https://doi.org/10.1542/peds.2020-0702 CrossRefPubMedPubMedCentral

14.

Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y (2020) SARS-CoV-2 infection in children. N Engl J Med 382(17):1663–1665CrossRefPubMed

15.

Balasubramanian S, Rao NM, Goenka A, Roderick M, Ramanan AV (2020) Coronavirus disease 2019 (COVID-19) in children—what we know so far and what we do not. Indian Pediatr 57(5):435–442. https://doi.org/10.1007/s13312-020-1819-5 CrossRefPubMedPubMedCentral

16.

Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, Mosca M, Bombardieri S (2020) COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 38(2):175–180PubMed

17.

Society TGR, of Rheumatologists PA (2020) Recommendations regarding COVID19 infection in rheumatic patients in Greece. Mediterr J Rheumatol 31(1):6

18.

Pham-Huy A (2019) Inborn errors of immunity: the missing link in infectious diseases susceptibility. Off J Assoc Med Microbiol Infect Dis Can 4(2):51–54

19.

Batu ED, Özen S (2020) Implications of COVID-19 in pediatric rheumatology. Rheumatol Int. https://doi.org/10.1007/s00296-020-04612-6 CrossRefPubMedPubMedCentral

20.

Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL (2020) Psychopharmacology of COVID-19. Psychosomatics. https://doi.org/10.1016/j.psym.2020.05.006 CrossRefPubMedPubMedCentral

21.

La Regina M, Ben-Chetrit E, Gasparyan AY, Livneh A, Ozdogan H, Manna R (2013) Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol 31(3 Suppl 77):41–46PubMed

22.

Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD (2015) Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 11(11):1781–1794. https://doi.org/10.1517/17425255.2015.1076391 CrossRefPubMed

23.

Piantoni S, Colombo E, Airò P, Tincani A, Brucato A, Franceschini F, Andreoli L, Furloni R, Scarsi M (2020) The rationale for the use of colchicine in COVID-19: comments on the letter Cumhur Cure M et al. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05232-y CrossRefPubMedPubMedCentral

24.

Parra-Medina R, Sarmiento-Monroy JC, Rojas-Villarraga A, Garavito E, Montealegre-Gómez G, Gómez-López A (2020) Colchicine as a possible therapeutic option in COVID-19 infection. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05247-5 CrossRefPubMedPubMedCentral

25.

Piantoni S, Patroni A, Toniati P, Furloni R, Franceschini F, Andreoli L, Scarsi M (2020) Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease. Rheumatol (Oxford, Engl) 59(7):1769–1770. https://doi.org/10.1093/rheumatology/keaa217 CrossRef

26.

Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Degli Antoni A, Peruzzi L, Riella LV, Cravedi P, Maggiore U (2020) COVID-19 in kidney transplant recipients. Am J Transplant. https://doi.org/10.1111/ajt.15891 CrossRefPubMedPubMedCentral

27.

Kobak S (2020) COVID-19 infection in a patient with FMF: does colchicine have a protective effect? Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217882 CrossRefPubMed

28.

Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, Dolianitis K, Randou E, Syrigos K, Kotanidou A, Koulouris NG, Milionis H, Sipsas N, Gogos C, Tsoukalas G, Olympios CD, Tsagalou E, Migdalis I, Gerakari S, Angelidis C, Alexopoulos D, Davlouros P, Hahalis G, Kanonidis I, Katritsis D, Kolettis T, Manolis AS, Michalis L, Naka KK, Pyrgakis VN, Toutouzas KP, Triposkiadis F, Tsioufis K, Vavouranakis E, Martinèz-Dolz L, Reimers B, Stefanini GG, Cleman M, Goudevenos J, Tsiodras S, Tousoulis D, Iliodromitis E, Mehran R, Dangas G, Stefanadis C (2020) Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open 3(6):e2013136. https://doi.org/10.1001/jamanetworkopen.2020.13136 CrossRefPubMedPubMedCentral

29.

Pedersen SF, Ho YC (2020) SARS-CoV-2: a storm is raging. J Clin Invest 130(5):2202–2205. https://doi.org/10.1172/jci137647 CrossRefPubMedPubMedCentral

30.

D'Antiga L (2020) Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplant 26(6):832–834. https://doi.org/10.1002/lt.25756 CrossRef

31.

Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, Gentileschi S, Bennett D, Falsetti P, Lanzarone N, Bellisai F, Barreca C, D'Alessandro R, Cantarini L, Frediani B (2020) COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217681 CrossRefPubMed

32.

Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, Sufka P, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann JS, Costello W, Robinson P, Machado PM, Yazdany J (2020) Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2(5):e250–253. https://doi.org/10.1016/s2665-9913(20)30095-3 CrossRefPubMedCentralPubMed

33.

Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R (2020) Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs. J Rheumatol. https://doi.org/10.3899/jrheum.200483 CrossRefPubMed

34.

Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, Antinori S, Galli M (2020) COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 38(2):337–342PubMed

35.

Cron RQ, Chatham WW (2020) The rheumatologist's role in COVID-19. J Rheumatol 47(5):639–642. https://doi.org/10.3899/jrheum.200334 CrossRefPubMed

36.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034CrossRefPubMedPubMedCentral

37.

Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, Justet A (2020) Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217706 CrossRefPubMed

38.

Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R (2020) COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev 19(5):102523. https://doi.org/10.1016/j.autrev.2020.102523 CrossRefPubMedPubMedCentral

Title: Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic
Authors: Fatih Haslak
Mehmet Yildiz
Amra Adrovic
Sezgin Sahin
Oya Koker
Ayten Aliyeva
Kenan Barut
Ozgur Kasapcopur
Publication date: 01-09-2020
Publisher: Springer Berlin Heidelberg
Keywords: Colchicine
Severe Acute Respiratory Syndrome Coronavirus
SARS-CoV-2
COVID-19
Polymerase Chain Reaction
Autoinflammatory Diseases
Familial Mediterranean Fever
Published in: Rheumatology International / Issue 9/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04645-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2020

Assessing the diet quality of individuals with rheumatic conditions: a cross-sectional study

Association between daily level of objective physical activity and C-Reactive protein in a representative national sample of adults with self-reported diagnosed arthritis or fibromyalgia

Anxiety and depression in reproductive age women with rheumatic diseases

Back pain, ankylosing spondylitis and social media usage; a descriptive analysis of current activity

Adequately dosed aerobic physical activity in people with axial spondyloarthritis: associations with physical therapy

Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim–Chester disease: case-based review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials